About AREVA Med
AREVA Med is an AREVA subsidiary created in 2009 to develop innovative therapies to fight cancer.
Learn more about nuclear medicine and targeted alpha therapy (TAT) with lead-212, and about our ongoing research.
AREVA Med launched the first Phase 1 clinical trial of lead-212 (patient enrollment completed in 2014).
News & Materials
Read about the latest news and events, watch a video, or download our brochure.
Macrocyclics, an AREVA Med company, is the global leader in chelating agent technologies for medicine.
RadioMedix and AREVA Med - SBIR NCI Contract awarded to develop targeted alpha-emitter therapy of neuroendocrine tumors with lead-212Read more
AREVA Med appoints Julien Dodet as new Chief Executive OfficerRead more